Inflammatory bowel diseases (IBD) are chronic immune disorders, whichnecessitate long-term dependence on powerful drugs. Recently, the use of natural product-based therapieshas emerged as a promising intervention for IBD. Aphanizomenon flose-aquae (AFA) is a unicellular bluegreenmicroalgae, traditionally used for its health-enhancing antioxidant and anti-inflammatory properties;we aimed to evaluate its protective effects on animal model of experimental colitis.Colitis was induced in rat by intracolonic instillation of 15 mg of 2,4-dinitrobenzene sulfonic acid (DNBS).Rats received AFA (100 mg/kg/d) by oral route, 4 days before and 6 days after colitis induction. The effectsof AFA on DNBS-induced colitis were evaluated by assessment of macroscopic, microscopic signs of colitisand by biochemical assay of the markers of inflammation.Obvious reduction of body weight, loose faeces/ diarrhoea, increase in colon weight/length ratio, colonicinflammation, mucosa injuries and increase in myeloperoxidase levels were observed in DNBS- groups.AFA pre-treatment improved body-weight, stool consistency, and colon shortening as well as attenuated theextent of colonic damage, likely protecting the mucosal epithelium. Colonic histopathological changes,cellular neutrophil infiltration and the subsequent increase in colonic myeloperoxidase levels induced byDNBS, were also reduced after AFA administration. AFA treatment was ineffective in control group.The present study, for the first time, shows the protective effects of AFA extract on DNBS-induced colitis inrats. Further studies could be addressed to evaluate if Blue-green alga AFA could be used as nutraceuticals inthe treatment of the IBD.
|Number of pages||1|
|Publication status||Published - 2018|